Doxazosin to treat hypertension: It's time to take it personally - A retrospective analysis of 19495 patients

Journal of Hypertension

Volumn 32, Issue 5, 2014, Pages 1132-1137

  Wolak, Talya ^a   Toledano, Ronen ^a,b   Novack, Victor ^a,b   Sharon, Amir ^b   Shalev, Aryeh ^a,c   Wolak, Arik ^a,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Clinical Research Center   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

cardiac ischemia; doxazosin; hypertension; receptor blocker

Indexed keywords

ACETYLSALICYLIC ACID; ALFUZOSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOBUTAMINE; DOXAZOSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PRAZOSIN; TAMSULOSIN; TERAZOSIN; THALLIUM; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MYOCARDIAL PERFUSION IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREADMILL EXERCISE; MIDDLE AGED;

AGED; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84898428960     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000119     Document Type: Article

References (28)

1. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49:295-320.
2. Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate Suppl 1990; 3:75-84.
3. Grimm RH Jr, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996; 275:1549-1556.
4. Shibasaki S, Eguchi K, Matsui Y, Ishikawa J, Hoshide S, Ishikawa S, et al. Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study. J Hypertens 2009; 27:1252-1257.
5. Chapman N, Chen CY, Fujita T, Hobbs FD, Kim SJ, Staessen JA, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens 2010; 28:1796-1803.
6. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003; 41:866-869.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
8. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
9. Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS. Stress protocols and tracers. J Nucl Cardiol 2006; 13:e80-90.
10. Germano G, Kavanagh PB, Slomka PJ, Van Kriekinge SD, Pollard G, Berman DS. Quantitation in gated perfusion SPECT imaging: the Cedars-Sinai approach. J Nucl Cardiol 2007; 14:433-454.
11. Germano GBD. Clinical gated cardiac SPECT, 2nd edn. Oxford: Blackwell Publishing; 2006; 139-171.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
13. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
14. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev 2007; 85:108-117; 165.
15. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther 2007; 81:311-315.
16. Lee MS, Flammer AJ, Lerman LO, Lerman A. Personalized medicine in cardiovascular diseases. Korean Circ JV 42 2012;583-591.
17. Jorgensen JT. A challenging drug development process in the era of personalized medicine. Drug Discov TodayV 16 2011;891-897.
18. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107:2900-2907.
19. Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press 2009; 18:74-77.
20. Banach M, Aronow WS. Blood pressure J-curve: current concepts. Curr Hypertens Rep 2012; 14:556-566.
21. Yamazaki T, Kohro T, Chujo M, Ishigaki M, Hashimoto T. The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the postmarketing surveillance data for valsartan in Japan (J-VALID). Hypertens Res 2013; 36:140-150.
22. Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, Kiehn J, et al. Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol 2008; 579:98-103.
23. Kyprianou N, Vaughan TB, Michel MC. Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiedebergs Arch Pharmacol 2009; 380:473-477.
24. Gonzalez-Juanatey JR, Iglesias MJ, Alcaide C, Pineiro R, Lago F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 2003; 107:127-131.
25. Osborn JL, DiBona GF, Thames MD. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther 1981; 216:265-269.
26. Shannon R, Chaudhry M. Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J 2006; 152:842-850.
27. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
28. Hillaert MA, Lentjes EG, Beygui F, Kemperman H, Asselbergs FW, Nathoe HM, et al. Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J 2011; 162:585-596.